Articles

Offerings include treatment plans for a considerable number of illnesses and conditions, company says. 

Optum Perks Follows Recent Trend of Expanded Telehealth Options

Study describes how a game theoretic model can successfully analyze how adoption of blockchain technology can reveal quality information. 

Using Blockchain to Minimize Consumers’ Risk Aversion Toward Generic Drugs

Data from prior Phase II study showed signs of pridopidine slowing disease progression in patients with amyotrophic lateral sclerosis.

Prilenia Announces Plans to Initiate Global Phase III Study of Novel ALS Treatment

NK010, which showed promising anti-tumor activity and safety in preclinical studies, will be evaluated in a Phase I clinical trial for ovarian cancer.

FDA Clears Trial of Non-Genetically Modified Natural Killer Cell Therapy

The addressable treatment market for osteopenia is projected to reach more than $30 billion in the United States and $100 billion globally.

Osteoboost Device Gains FDA Clearance to Treat Osteopenia in Postmenopausal Women

Acquisition is expected to strengthen company’s CDMO business, while establishing a footprint in the generics space.

Bora Pharmaceuticals Completes $210 Million Purchase of Upsher-Smith 

Phase Ib study evaluated satri-cel in patients with advanced gastric/gastroesophageal cancer or pancreatic cancer who had progressed on or were intolerant of prior systemic therapy.

Satri-Cel CAR T-Cell Therapy Shows Promising Safety, Efficacy in Gastric, Pancreatic Cancer

Opdivo (nivolumab) with Yervoy (ipilimumab) showed a 79% drop in the risk of disease progression or death compared to chemotherapy in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.

Opdivo Plus Yervoy Shows Significantly Improved Progression-Free Survival in Metastatic Colorectal Cancer 

Sandoz will buy Cimerli (ranibizumab-eqrn), an interchangeable biosimilar to Lucentis (ranibizumab), for an upfront cash payment of $170 million.

Sandoz, Coherus BioSciences Reach Agreement on Sale of Lucentis Biosimilar

Today's approval amends the accelerated approval granted by the FDA in April 2019 to Balversa (erdafitinib) for patients with metastatic urothelial carcinoma with susceptible FGFR2 or FGFR3 alterations following prior treatment with platinum-containing chemotherapy.

News